Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
Kristina Lindemann(Norwegian Cancer Society), Anna DeFazio(The University of Sydney), Kathryn Alsop(Peter MacCallum Cancer Centre), Sián Fereday(Peter MacCallum Cancer Centre), Cristina Mapagu(The University of Sydney), Bo Gao(Sun Yat-sen University), Paul R. Harnett(The University of Sydney), Nadia Traficante(The University of Melbourne), Catherine Emmanuel(Peter MacCallum Cancer Centre), David D.L. Bowtell(The University of Melbourne)
Cited by 52
Related Papers
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k